NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Mersana Therapeutics Inc (NASDAQ: MRSN)

 
MRSN Technical Analysis
5
As on 9th Jun 2023 MRSN STOCK Price closed @ 8.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.37 & Strong Buy for SHORT-TERM with Stoploss of 5.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MRSNSTOCK Price

Open 8.67 Change Price %
High 8.81 1 Day -0.09 -1.04
Low 8.44 1 Week 1.03 13.70
Close 8.55 1 Month 4.83 129.84
Volume 1700000 1 Year 2.67 45.41
52 Week High 8.83 | 52 Week Low 2.84
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
MRSN
Daily Charts
MRSN
Intraday Charts
Whats New @
Bazaartrend
MRSN
Free Analysis
 
MRSN Important Levels Intraday
RESISTANCE9.26
RESISTANCE9.03
RESISTANCE8.89
RESISTANCE8.75
SUPPORT8.35
SUPPORT8.21
SUPPORT8.07
SUPPORT7.84
 
MRSN Forecast May 2024
4th UP Forecast14.31
3rd UP Forecast12.46
2nd UP Forecast11.32
1st UP Forecast10.18
1st DOWN Forecast6.92
2nd DOWN Forecast5.78
3rd DOWN Forecast4.64
4th DOWN Forecast2.79
 
MRSN Weekly Forecast
4th UP Forecast11.63
3rd UP Forecast10.64
2nd UP Forecast10.03
1st UP Forecast9.42
1st DOWN Forecast7.68
2nd DOWN Forecast7.07
3rd DOWN Forecast6.46
4th DOWN Forecast5.47
 
MRSN Forecast2024
4th UP Forecast20.63
3rd UP Forecast16.76
2nd UP Forecast14.36
1st UP Forecast11.97
1st DOWN Forecast5.13
2nd DOWN Forecast2.74
3rd DOWN Forecast0.34
4th DOWN Forecast-3.53
 
 
MRSN Other Details
Segment EQ
Market Capital 651594432.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MRSN Address
MRSN
 
MRSN Latest News
 
Your Comments and Response on Mersana Therapeutics Inc
 
MRSN Business Profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service